Article Figures & Data
Figures
- FIGURE 1.
68Ga-PSMA-11 PET demonstrates increased PSMA expression in prostate cancer xenografts with inhibition of AR. (A) Ratio of SUVmean at day 7 to day 0 increased an average of 72% with orchiectomy and 105% with ARN-509 compared with vehicle. (B) Visual assessment of 68Ga-PSMA-11 PET demonstrates clear increase in uptake in xenografts in response to ARN-509 (middle row) and orchiectomy (bottom row), compared with controls treated with vehicle (top row). *P = 0.007. **P = 0.013. ID = injected dose; ROI = region of interest; RX = treatment.
- FIGURE 2.
(A and B) Coronal maximum-intensity projections of patient with castration-sensitive metastatic prostate cancer imaged using 68Ga-PSMA-11 before ADT (A) and after ADT (B) demonstrate marked increase in uptake in lesions. (C) Each visualized lesion demonstrated increased uptake, averaging more than 7 times the initial uptake. (D and E) Numerous lesions (13 of 22) were visualized only on posttreatment imaging, as exemplified by the upper thoracic osseous metastasis seen on these axial PET images. (F and G) Other lesions increased in size and had increased uptake on posttreatment imaging, as exemplified by the lesion seen on these axial PET images.
- FIGURE 3.
Examples of lesions seen only on post-ADT PSMA PET. (A) Pretreatment PET image demonstrates single lesion (circled) in right acetabulum. (B) Additional non–PSMA-avid right acetabular lesion (arrow) is seen just lateral to larger lesion on MR image of same location. (C) On post-ADT PET image, numerous additional lesions are seen, including adjacent acetabular lesion (arrow). (D) This lesion (arrow) is again demonstrated on enhanced T1-weighted MR image.
Jump to section
Related Articles
Cited By...
- Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
- Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
- Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values <= 0.5 ng/mL
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
- Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone
- Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
- 11C-Choline Pharmacokinetics in Recurrent Prostate Cancer
- 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters
- More {alpha} Than {beta} for Prostate Cancer?
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer